Thomas Adam Abrams

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Brian Matthew Wolpin · 10 shared papers, 2012–2026 · strength 1.21
   • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
2. James M. Cleary · 6 shared papers, 2023–2026 · strength 0.91
   • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
3. Douglas Adam Rubinson · 5 shared papers, 2023–2026 · strength 0.72
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
4. Kimberly J. Perez · 5 shared papers, 2023–2026 · strength 0.72
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
5. Jonathan Andrew Nowak · 4 shared papers, 2024–2026 · strength 0.63
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
6. Matthew B.B. Yurgelun · 4 shared papers, 2023–2026 · strength 0.60
   • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
7. Harshabad Singh · 4 shared papers, 2023–2026 · strength 0.60
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
8. Srivatsan Raghavan · 4 shared papers, 2023–2026 · strength 0.59
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
9. Andrew J. Aguirre · 4 shared papers, 2023–2026 · strength 0.59
   • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
   • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
   • Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
10. Joseph Douglas Mancias · 3 shared papers, 2024–2026 · strength 0.50
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
11. Kimmie Ng · 4 shared papers, 2012–2026 · strength 0.49
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
12. Andressa Dias Costa · 3 shared papers, 2024–2026 · strength 0.48
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
13. Rishi Surana · 3 shared papers, 2024–2026 · strength 0.47
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
14. Colin D. Weekes · 3 shared papers, 2023–2026 · strength 0.47
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
15. Leah H. Biller · 3 shared papers, 2023–2025 · strength 0.42
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
    • Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
16. Brandon M. Huffman · 3 shared papers, 2023–2025 · strength 0.42
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
    • Paper A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemci… DOI 10.1158/1078-0432.ccr-23-2005↗
17. Lawrence Scott Blaszkowsky · 4 shared papers, 2012–2026 · strength 0.37
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Ca… DOI 10.1093/oncolo/oyad002↗
    • Paper Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local cont… DOI 10.1016/j.prro.2013.07.006↗
18. Sarah Slater · 2 shared papers, 2025–2026 · strength 0.34
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
19. Aparna R. Parikh · 2 shared papers, 2025–2026 · strength 0.34
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
20. ANDREA C Enzinger · 2 shared papers, 2025–2026 · strength 0.33
    • Paper Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomi… DOI 10.1038/s43018-026-01165-8↗
    • Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
21. Victoire Cardot‐Ruffino · 2 shared papers, 2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
22. Lestat R. Ali · 2 shared papers, 2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
23. Osama E. Rahma · 2 shared papers, 2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
24. Stephanie K. Dougan · 2 shared papers, 2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
25. David P. Ryan · 3 shared papers, 2012–2026 · strength 0.24
    • Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
    • Paper Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local cont… DOI 10.1016/j.prro.2013.07.006↗
    • Paper A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable … DOI 10.1007/s10637-011-9708-3↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.